Johanna Raymond has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cartographie des activités de pharmacie clinique dans la filière de l’urgence adulte en France

    by Johanna Raymond, Loriane Viault, Marion Laureau, Catherine Chenailler, Rémi Varin, Eric Barat

  • Open Access

    An Overview of Opioid Prescription Patterns among Non-Opioid Users Following Emergency Department Admission

    by Miriam Zeino, Romain Léguillon, Pauline Brevet, Baptiste Gerard, Catherine Chenailler, Johanna Raymond, Lucas Bibaut, Sophie Pouplin, Luc Marie Joly, Rémi Varin, et al.

    The evolving landscape of opioid prescription practices necessitates a comprehensive understanding of emerging patterns, particularly among new opioid users discharged from emergency departments. This study delves into the intricate realm of opioid utilization by elucidating the prevalence of their prescriptions. A retrospective analysis of electronic health records was conducted, including a cohort of 71 patients who received opioid prescriptions upon discharge from emergency departments from 1 January 2022 to 30 June 2022. Demographic characteristics and prescription details were systematically examined. This study illuminates tramadol’s prominence, with 84% of prescriptions and a Defined Daily Dose (DDD) morphine equivalent of 60 mg, as the primary choice as a new opioid, a finding that draws attention due to the closely aligned dosages with morphine equivalents. This discovery prompts a critical reassessment of tramadol’s therapeutic role, considering its multifaceted nature encompassing serotonergic effects and heightened fall risks. This study advocates for a nuanced and vigilant approach to tramadol prescription, cognizant of its potential risks and therapeutic implications, and highlights the imperative of optimizing data quality and traceability within electronic health records to enhance patient care and facilitate future research endeavors.

  • Open Access

    Enhancing Medication Adherence in Asthma and COPD: Crafting a Targeted Pharmaceutical Interview Framework

    by Eric Barat, Elisa Dubec, Johanna Raymond, Luc-Marie Joly, Rémi Varin, Romain Léguillon

    (1) Background: Asthma and Chronic Obstructive Pulmonary Disease (COPD ) are major global health issues, impacting morbidity, mortality, and healthcare costs. Despite the proven benefits of pharmacist involvement in managing these conditions, their potential in hospitals remains underused. This study aimed to identify patients at high risk of rehospitalisation post-exacerbation of asthma or COPD, to target pharmaceutical interventions. (2) Methods: Data from the University Hospital for January-December 2019 on adult admissions for asthma/COPD were analyzed, focusing on demographics, hospitalization, and clinical outcomes. (3) Results: Among the 140 patients enrolled, a significant majority (91%) underwent adjustments in their treatment regimens during their hospital stay, and nearly 59% faced readmission within six months. A survival analysis highlighted a notable disparity in the rates of rehospitalisation-free survival between patients with asthma and those with COPD, identifying COPD patients as having a higher susceptibility to rehospitalisation. (4) Conclusion: The study found COPD pa-tients at greater risk but didn't specify a priority profile, suggesting the necessity for broad, cus-tomized interventions to improve outcomes and reduce healthcare strain.

  • Pharmacist tracking and correction of medication errors: An improvement project in the observation ward of the emergency department

    by Johanna Raymond, Pierre Parrein, Eric Barat, Catherine Chenailler, Gaëlle Decreau-Gaillon, Rémi Varin, Luc-Marie Joly


  • Open Access

    Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review

    by Johanna Raymond, Laurent Imbert, Thibault Cousin, Thomas Duflot, Rémi Varin, Julien Wils, Fabien Lamoureux

    Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed.